Whole-human HER2 antibodies, and coding genes and application thereof

A fully human, antibody technology, applied in applications, antibodies, genetic engineering, etc., can solve problems such as recurrence and unmet needs
CN104530236AActive Publication Date: 2015-04-22GENOR BIOPHARMA
2 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
GENOR BIOPHARMA
Publication Date
2015-04-22

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of medicinal chemistry, and particularly relates to two whole-human HER2 antibodies, and coding genes and an application thereof. The invention provides the two whole-human HER2 antibodies, wherein an amino acid sequence of a heavy chain variable region of one HER2 antibody is SEQ ID NO:1, and an amino acid sequence of a light chain variable region is SEQ ID NO:2; an amino acid sequence of a heavy chain variable region of the other HER2 antibody is SEQ ID NO:10, and an amino acid sequence of a light chain variable region is SEQ ID NO:11. The whole-human HER2 antibodies can reduce transfusion reactions and immunogenicity, improve drug safety and have better pharmacokinetic characteristics. In addition, the whole-human antibodies can be combined with other HER2 positive tumor therapeutic agents for use in treatment of HER2 positive tumors.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of antibodies, in particular to a fully human HER2 antibody, its coding gene and its application. Background technique

[0002] Breast cancer is the most common malignancy in women worldwide. The HER family regulates the growth and development of normal mammary glands, and overexpression of HER2 is associated with breast cancer. Trastuzumab (trastuzumab), trade name Herceptin (Herceptin), is the first humanized monoclonal antibody for the treatment of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer drug. Although Herceptin has become the standard treatment for HER2-positive malignancies, 40% of patients still do not respond to Herceptin. Furthermore, drug resistance has become a common and serious problem in anti-HER2 therapeutics. Redundancy of growth factors and crosstalk between intracellular signaling pathways are thought to be major contributors to drug resistance i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More